Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
|Videos|December 13, 2019
Transplant-Eligible Newly Diagnosed Multiple Myeloma
Transplant-Eligible Newly Diagnosed Multiple Myeloma
Advertisement
Case: 75-Year-Old Woman with Newly Diagnosed Multiple Myeloma
History and Presentation:
- 75-year-old woman; diabetic on metformin, no history of coronary artery disease or other comorbidities
- κ light chain multiple myeloma diagnosed November 2019
- Durie-Salmon Stage IIIA, ISS Stage 2
- Laboratory findings
- Total proteinuria 5.82 g/day
- Bence Jones protein (BJP) 3.6 g/day
- Hypogammaglobulinemia
- Albumin 3.9 g/dL
- β2-microglobulin 4.7 mg/L
- Creatinine 1.7 mg/dl
- No paraprotein peak but kappa light chain 2000 with lambda light chain at 1
- Kappa/lambda ratio=2000
- Bone marrow biopsy
- Cellularity 25% with 80% plasma cells
- Cytogenetics 46, XX
- FISH no abnormalities
- Imaging
- Skeletal survey: extensive lytic bone disease with healing fractures of left 7thand the 8thribs
- MRI of the spine: multiple compression fractures
- MRI of the pelvis: diffuse marrow infiltrative changes due to myeloma
- Cytogenetics/FISH: no adverse cytogenetics
- ECOG PS: 1
- Patient was started on D-VRd
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5